Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. (January 2019)

• Record Type: Journal Article
• Authors: Sheel, A. R. G.; Harrison, S.; Sarantitis, I.; Nicholson, J. A.; Hanna, T.; Grocock, C.; Raraty, M.; Ramesh, J.; Farooq, A.; Costello, E.; Jackson, R.; Chapman, M.; Smith, A.; Carter, R.; Mckay, C.; Hamady, Z.; Aithal, G. P.; Mountford, R.; Ghaneh, P.; Hammel, P.; Lerch, M. M.; Halloran, C.; Pereira, S. P.; Greenhalf, W.
• Is Part Of: American journal of gastroenterology. Volume 114:Number 1(2019)
• Publication Date: 2019-01
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.1038/s41395-018-0395-y
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : OBJECTIVES: Intraductal papillary mucinous neoplasms (IPMNs) are associated with risk of pancreatic ductal adenocarcinoma (PDAC). It is unclear if an IPMN in individuals at high risk of PDAC should be considered as a positive screening result or as an incidental finding. Stratified familial pancreatic cancer (FPC) populations were used to determine if IPMN risk is linked to familial risk of PDAC. METHODS: This is a cohort study of 321 individuals from 258 kindreds suspected of being FPC and undergoing secondary screening for PDAC through the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC). Computerised tomography, endoscopic ultrasound of the pancreas and magnetic resonance imaging were used. The risk of being a carrier of a dominant mutation predisposing to pancreatic cancer was stratified into three even categories (low, medium and high) based on: Mendelian probability, the number of PDAC cases and the number of people at risk in a kindred. RESULTS: There was a median (interquartile range (IQR)) follow-up of 2 (0–5) years and a median (IQR) number of investigations per participant of 4 (2–6). One PDAC, two low-grade neuroendocrine tumours and 41 cystic lesions were identified, including 23 IPMN (22 branch-duct (BD)). The PDAC case occurred in the top 10% of risk, and the BD-IPMN cases were evenly distributed amongst risk categories: low (6/107), medium (10/107) and high (6/107) ( P = 0.63). CONCLUSIONS: The risk of finding BD-IPMN was independent of genetic predisposition and so they should be managed according to guidelines for incidental finding of IPMN.